Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 44c; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.33 -1.84%
EPS Growth %: -60.5%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -60.5%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($1.04), $0.44 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $50.52 million versus the consensus estimate of $61.78 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $262.1 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Loop Capital Starts Affirm Holdings (AFRM) at Buy
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
